About 4P Pharma
4P Pharma is a company based in Lille (France) founded in 2014. 4P Pharma has raised $18.49 million across 2 funding rounds from investors including Bpifrance and Satt Lutech. 4P Pharma offers products and services including 4P004 and 4P025. 4P Pharma operates in a competitive market with competitors including Indivior, Biotie, Ethypharm, Braeburn and Opiant Pharmaceuticals, among others.
- Headquarter Lille, France
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website 4p-pharma.com
- Social LinkedIn X
- Total Equity Funding$18.49M (USD)
in 2 rounds
- Latest Funding Round$16.04M (USD), Series B
Apr 2024
- InvestorsBpifrance
& 1 more
Products & Services of 4P Pharma
4P Pharma offers a comprehensive portfolio of products and services, including 4P004 and 4P025.
GLP-1 analog for treating osteoarthritis and reducing inflammation.
AI-derived treatment for primary sclerosing cholangitis liver condition.
Funding Insights of 4P Pharma
4P Pharma has successfully raised a total of $18.49M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $16.04 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $18.49M
- Total Rounds 2
- Last Round Series B — $16.04M
- First Round $2.45M
(Jun 2021)
- Investors Count 2
All 2 funding rounds of 4P Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | $16.04M | Series B | – | – | – |
| Jun 2021 | $2.45M | Series A | – | – |
2 investors in total: 2 institutional.
Investors in 4P Pharma
4P Pharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Bpifrance and Satt Lutech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Facilitates maturation of inventions into commercial innovations for businesses and researchers. | 2012 | sattlutech.com | Paris, France | |
Corporate consultancy, advisory, and funding services are provided to businesses. | 2012 | bpifrance.com | Maisons Alfort, France |
Investor details for 4P Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of 4P Pharma
10 people are tracked at 4P Pharma (3 in leadership, 7 in team).
| Name | Role | Group |
|---|---|---|
Mathilde Mérot | Director Of Regulatory Affairs And Clinical Operations | Leadership |
Emmanuelle Lopez | Chief Financial Officer | Leadership |
Frédéric Marin | Chief Development Officer | Leadership |
William Sibran | Ingénieur D’études Senior | Team |
Yu Wang | China Representative | Team |
Roselina Lam | Business Development And Licensing-in Manager | Team |
Céline Martin | R&d Operations | Team |
Anne-Claire Gaudiez | Business Developer And Licensing-in | Team |
Mohammed Boujnan | Responsable Comptable | Team |
Adrien Berdah | Investor | Team |
Complete people profiles for 4P Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of 4P Pharma
3 dated milestones of 4P Pharma across 10 years, from founding to its latest funding, stage changes and deals.
- Founded 4P Pharma is founded.
- Funding First funding round of $2.5M.
- Funding Latest funding round, Series B, of $16.0M.
Competitors of 4P Pharma
4P Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indivior, Biotie, Ethypharm, Braeburn and Opiant Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| indivior.com | 2014 | Richmond Hill, United States | – | 1,051 | Therapeutics for opioid addiction treatment are developed and commercialized. | |
| biotie.com | 1998 | Turku, Finland | $149.81M | 27 | Drugs for neurodegenerative and psychiatric disorders are developed by Biotie. | |
| ethypharm.com | 1977 | Saint Cloud, France | $248.09M | – | Therapies for pain and addiction treatment are developed. | |
| braeburnrx.com | 2012 | Philadelphia, United States | $110M | – | Long-acting therapies for opioid addiction and chronic pain are developed. | |
| opiant.com | 2005 | Santa Monica, United States | – | 31 | Therapeutics for addictive and eating disorders are developed. | |
| amygns.com | 2015 | San Francisco, United States | $7.05M | – | Therapies for substance use disorders are developed by Amygdala Neurosciences. | |
| cessationtherapeutics.com | 2017 | San Jose, United States | $6.76M | – | Developer of immunotherapy based vaccines to manage addictions | |
| titanpharm.com | 1992 | San Francisco, United States | – | 11 | A specialty pharmaceutical company developing proprietary therapeutics for select chronic diseases | |
| aelisfarma.com | 2013 | Bordeaux, France | $14.04M | – | Developer of small molecule drugs targeting CB1 receptor for CNS diseases |
Detailed competitors of 4P Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to 4P Pharma
10 companies that operate in the same segment as 4P Pharma (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about 4P Pharma
4P Pharma was founded in 2014 and raised its 1st funding round 7 years after it was founded.
4P Pharma is headquartered in Lille, France. It is registered at Lille, Hauts-de-france, France.
4P Pharma is a funded company, having raised a total of $18.49M across 2 funding rounds to date. The company's 1st funding round was a Series A of $2.45M, raised on Jun 2021.
4P Pharma was established in 2014 in Lille, France, as a preclinical biotech startup. Drug candidates are in-licensed from university research and small biotechs, then advanced to Phase IIIa trials before out-licensing. Operations target cancer, inflammatory diseases, and addiction treatments through New Chemical Entities, biologics, repositioned generics, and fixed-dose combinations. No molecules have entered clinical stages yet.
4P Pharma's top competitors include Indivior, Ethypharm and Amygdala Neurosciences.
4P Pharma offers 4P004 and 4P025.
4P Pharma has 2 investors. Key investors include Bpifrance, and Satt Lutech.